← Human Trials & Peer-Reviewed Studies
Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency.
Plain-language guide to PMID 11966737 (2002): double-blind randomized controlled trial of Human Growth Hormone in 32 adults.
Key Facts
- PMID
- 11966737
- Journal
- Clinical endocrinology
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Smith JC et al. (7 authors)
- DOI
- 10.1046/j.1365-2265.2002.01493.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Human Growth Hormone, published as a randomized controlled trial.
Who Took Part
The study group was 32 adults.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Human Growth Hormone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the adults nor the staff measuring them knew who was on Human Growth Hormone, so expectations could not easily colour the readings.
Some adults received a placebo instead of Human Growth Hormone, giving a reference point.
Lipid hydroperoxides (HPOs) in plasma were measured using the ferrous oxidation with xylenol orange (FOX) assay.
The susceptibility of LDL to oxidation was assessed by the copper-catalysed lag phase of LDL oxidation.
Neutrophil O(-)(2)- generating capacity was assessed by a lucigenin-based chemiluminescent assay of NADPH oxidase activity.
Body composition was assessed using bioelectrical impedance analysis.
What Was Measured
PubMed files the paper under topics including Human Growth Hormone, Hypopituitarism, Lipid Peroxidation, Lipoproteins, LDL, Neutrophils, Oxidative Stress and Superoxides.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Human Growth Hormone in 32 adults.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2002 (Clinical endocrinology), a journal based in England.
More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.
Related Library Page
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.